IL270365A - - Google Patents
Info
- Publication number
- IL270365A IL270365A IL27036519A IL27036519A IL270365A IL 270365 A IL270365 A IL 270365A IL 27036519 A IL27036519 A IL 27036519A IL 27036519 A IL27036519 A IL 27036519A IL 270365 A IL270365 A IL 270365A
- Authority
- IL
- Israel
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/99—Serum-free medium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2309—Interleukin-9 (IL-9)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2318—Interleukin-18 (IL-18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2333—Interleukin-33 (IL-33)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1707048.3A GB201707048D0 (en) | 2017-05-03 | 2017-05-03 | Expansion of gamma delta cells, compositions, and methods of use thereof |
| PCT/EP2018/061413 WO2018202808A2 (en) | 2017-05-03 | 2018-05-03 | Expansion of gamma delta t cells, compositions, and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL270365A true IL270365A (cg-RX-API-DMAC7.html) | 2019-12-31 |
| IL270365B1 IL270365B1 (en) | 2024-06-01 |
| IL270365B2 IL270365B2 (en) | 2024-10-01 |
Family
ID=59010925
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL270365A IL270365B2 (en) | 2017-05-03 | 2018-05-03 | Expansion of gamma delta t cells, compositions, and methods of use thereof |
| IL319114A IL319114A (en) | 2017-05-03 | 2018-05-03 | Expansion of gamma delta T cells, compositions and methods for use thereof |
| IL312633A IL312633B2 (en) | 2017-05-03 | 2018-05-03 | Expansion of gamma delta t cells, compositions, and methods of use thereof |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL319114A IL319114A (en) | 2017-05-03 | 2018-05-03 | Expansion of gamma delta T cells, compositions and methods for use thereof |
| IL312633A IL312633B2 (en) | 2017-05-03 | 2018-05-03 | Expansion of gamma delta t cells, compositions, and methods of use thereof |
Country Status (14)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1814580B1 (en) | 2004-11-24 | 2016-08-10 | Fred Hutchinson Cancer Research Center | Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens |
| GB201707048D0 (en) | 2017-05-03 | 2017-06-14 | King S College London | Expansion of gamma delta cells, compositions, and methods of use thereof |
| GB201804701D0 (en) | 2018-03-23 | 2018-05-09 | Gammadelta Therapeutics Ltd | Lymphocytes expressing heterologous targeting constructs |
| GB201818243D0 (en) * | 2018-11-08 | 2018-12-26 | Gammadelta Therapeutics Ltd | Methods for isolating and expanding cells |
| KR20210111746A (ko) | 2018-11-08 | 2021-09-13 | 감마델타 테라퓨틱스 리미티드 | 세포를 단리 및 증식하는 방법 |
| CN109517793B (zh) * | 2018-11-30 | 2022-05-10 | 广州长峰生物技术有限公司 | 一种NK细胞和γδT细胞共培养的建立方法 |
| GB201909144D0 (en) * | 2019-06-25 | 2019-08-07 | Autolus Ltd | Culture medium |
| LT4051710T (lt) | 2019-10-31 | 2026-03-10 | Incyte Corporation | Priešnavikinė kompleksinė terapija, apimanti anti-cd19 antikūną ir gama delta ląsteles |
| IL293459A (en) * | 2019-12-03 | 2022-07-01 | Adicet Bio Inc | Methods for expanding γδ t-cell populations with multivalent agents and compositions thereof |
| US20210290674A1 (en) * | 2020-03-20 | 2021-09-23 | GammaDelta Therapeutics Ltd. | Methods for treating myeloid malignancies |
| WO2021186137A1 (en) | 2020-03-20 | 2021-09-23 | GammaDelta Therapeutics Limited | V delta1+ t cells for the treatment of myeloid malignancies |
| GB202006989D0 (en) | 2020-05-12 | 2020-06-24 | Gammadelta Therapeutics Ltd | Methods for isolating gamma delta t cells |
| GB202013962D0 (en) * | 2020-09-04 | 2020-10-21 | Gammadelta Therapeutics Ltd | Immunotherapy composition |
| CN113234675A (zh) * | 2021-03-31 | 2021-08-10 | 广西医科大学 | 一种γδT细胞以及采用体外制备γδT细胞的方法 |
| GB202105113D0 (en) * | 2021-04-09 | 2021-05-26 | Gammadelta Therapeutics Ltd | Novel method |
| WO2022221439A1 (en) * | 2021-04-14 | 2022-10-20 | The Trustees Of The University Of Pennsylvania | Methods to determine treatment efficacy with gamma-delta t cells |
| AU2022258567B2 (en) * | 2021-04-16 | 2026-06-18 | Acepodia Biotechnologies Ltd. | Novel compositions enriched in gamma delta t cells, methods of preparation, and uses thereof |
| WO2023069322A1 (en) * | 2021-10-20 | 2023-04-27 | University Of Pittsburgh – Of The Commonwealth System Of Higher Education | Methods and materials for expanding tumor infiltrating gamma-delta t cells |
| JP2025504363A (ja) * | 2022-01-05 | 2025-02-12 | インヒブルクス バイオサイエンシズ インコーポレイテッド | γδT細胞結合ポリペプチド及びその使用 |
| EP4680729A1 (en) * | 2023-03-17 | 2026-01-21 | Legend Biotech Ireland Limited | Methods of culturing v delta 1 t cells |
| WO2024209429A1 (en) | 2023-04-07 | 2024-10-10 | Takeda Pharmaceutical Company Limited | T cells for use in treating relapsed or refractory acute myeloid leukemia |
| WO2025017531A1 (en) | 2023-07-20 | 2025-01-23 | Takeda Pharmaceutical Company Limited | Grid-free methods for making gamma delta t cells |
| JP2026526851A (ja) * | 2023-07-26 | 2026-08-10 | ヤンセン バイオテツク,インコーポレーテツド | 細胞増殖のための材料及び方法 |
| WO2026096605A1 (en) * | 2024-10-31 | 2026-05-07 | Pointloma Biosciences, Inc. | Methods for activation and expansion of gamma delta t cells |
| WO2026110042A1 (en) * | 2024-11-19 | 2026-05-28 | King's College London | Methods of expansion of skin vdelta1+ gammadelta t cells and use of same |
| KR20260090785A (ko) * | 2024-12-09 | 2026-06-17 | 한국과학기술원 | 체내 지속성 및 항종양 효과가 향상된 세포치료제, 및 이의 제조방법 |
| WO2026133284A1 (en) | 2024-12-19 | 2026-06-25 | Takeda Pharmaceutical Company Limited | Methods of expanding and production of gammadelta t cells |
| EP4779306A1 (en) * | 2025-01-17 | 2026-07-22 | HUB Organoids IP B.V. | Co-cultures of organoids, stromal cells and immune cells |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6028176A (en) | 1996-07-19 | 2000-02-22 | Bayer Corporation | High-affinity interleukin-4 muteins |
| NZ511760A (en) | 1998-11-04 | 2003-10-31 | Hemosol Inc | Methods for the production of TcR gamma delta T cells |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| US20070122413A1 (en) | 2005-11-28 | 2007-05-31 | Sivakumar Pallavur V | Il-21 antagonists |
| WO2012088446A1 (en) | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| EP2710123B1 (en) | 2011-05-19 | 2017-07-12 | Instituto de Medicina Molecular | Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof |
| ES2539845B1 (es) | 2013-08-05 | 2016-04-13 | Universidad De Alicante | Procedimiento y síntesis de monolitos de carbón activo a partir de cascarilla de cacao |
| US9907820B2 (en) * | 2013-10-25 | 2018-03-06 | Board Of Regents, The University Of Texas System | Polyclonal gamma delta T cells for immunotherapy |
| UA123821C2 (uk) * | 2014-06-11 | 2021-06-09 | Полібіосепт Гмбх | Композиція для експансії лімфоцитів in vitro |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| RU2756247C2 (ru) * | 2014-11-17 | 2021-09-28 | Эдисет Био, Инк. | Генетически модифицированные гамма дельта т-клетки |
| US11150242B2 (en) * | 2015-04-10 | 2021-10-19 | President And Fellows Of Harvard College | Immune cell trapping devices and methods for making and using the same |
| JP6799895B2 (ja) * | 2015-06-09 | 2020-12-16 | リンファクト−リンフォサイト アクティベイション テクノロジーズ エス.エー. | TCRγδ+T細胞の生産方法 |
| US10829735B2 (en) | 2015-07-21 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Methods for improving the efficacy and expansion of immune cells |
| CN108473958A (zh) | 2015-10-30 | 2018-08-31 | 癌症研究技术有限公司 | 非造血组织驻留γδT细胞的扩增及这些细胞的用途 |
| GB201707048D0 (en) | 2017-05-03 | 2017-06-14 | King S College London | Expansion of gamma delta cells, compositions, and methods of use thereof |
-
2017
- 2017-05-03 GB GBGB1707048.3A patent/GB201707048D0/en not_active Ceased
-
2018
- 2018-05-03 KR KR1020257016628A patent/KR20250080907A/ko active Pending
- 2018-05-03 IL IL270365A patent/IL270365B2/en unknown
- 2018-05-03 JP JP2020512082A patent/JP2020518289A/ja active Pending
- 2018-05-03 AU AU2018262698A patent/AU2018262698B2/en active Active
- 2018-05-03 CA CA3062386A patent/CA3062386A1/en active Pending
- 2018-05-03 MX MX2019013001A patent/MX2019013001A/es unknown
- 2018-05-03 US US16/610,398 patent/US11655453B2/en active Active
- 2018-05-03 EP EP18725128.5A patent/EP3619298A2/en active Pending
- 2018-05-03 WO PCT/EP2018/061413 patent/WO2018202808A2/en not_active Ceased
- 2018-05-03 IL IL319114A patent/IL319114A/en unknown
- 2018-05-03 IL IL312633A patent/IL312633B2/en unknown
- 2018-05-03 CN CN201880044728.0A patent/CN110914410A/zh active Pending
- 2018-05-03 EA EA201992610A patent/EA201992610A1/ru unknown
- 2018-05-03 BR BR112019023076-9A patent/BR112019023076A2/pt active Search and Examination
- 2018-05-03 KR KR1020197035686A patent/KR102812405B1/ko active Active
-
2019
- 2019-10-31 MX MX2024004897A patent/MX2024004897A/es unknown
- 2019-11-04 PH PH12019502485A patent/PH12019502485A1/en unknown
-
2023
- 2023-01-12 US US18/153,900 patent/US12458698B2/en active Active
- 2023-02-17 JP JP2023022974A patent/JP7698672B2/ja active Active
-
2025
- 2025-06-13 JP JP2025099083A patent/JP2025134795A/ja active Pending
- 2025-09-10 AU AU2025230679A patent/AU2025230679A1/en active Pending
- 2025-10-06 US US19/351,054 patent/US20260174861A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR122021000189A2 (cg-RX-API-DMAC7.html) | ||
| BR112019008823A2 (cg-RX-API-DMAC7.html) | ||
| BR112020006084A8 (cg-RX-API-DMAC7.html) | ||
| BR112019025875B1 (pt) | Sistema de cilindro com estrutura de ocupação de movimento relativo | |
| BR112020011860B1 (pt) | Dispositivo cirúrgico para cortar uma lente dentro de um saco capsular de um olho | |
| BR112020006283B1 (pt) | Placa refinadora, e, refinador para tratamento mecânico de material orgânico/celulósico | |
| BR112020008714B1 (pt) | Uso de medicamentos serotoninérgicos para tratar trombocitopenia induzida por vírus | |
| BR112020006992B1 (pt) | Dispositivo de recolhimento e método para o recolhimento de uma embarcação | |
| BR112020003314B1 (pt) | Sistema terapêutico transdérmico para administração transdérmica de um agente ativo, seu método de fabricação, usos de emulsificante, e método para estabilizar uma mistura de revestimento bifásica | |
| BR112020003112B1 (pt) | Método de garantir a viabilidade de uma máquina para uma tarefa agendada | |
| BR112020002577B1 (pt) | Método de melhoria de rendimento de centrifugação dupla para purificação de óleo nutritivo | |
| BR112019016885B1 (pt) | Remodelagem de imagem integrada e codificação de vídeo | |
| BR112019027876B1 (pt) | Método de codificação para uma comunicação sem fio, codificador, método de decodificação, decodificador, aparelho de comunicação, meio de armazenagem legível por computador, e sistema de comunicações | |
| BR112020001354B1 (pt) | Método, em uma primeira estação base, para suportar posicionamento de um dispositivo móvel e primeira estação base para suportar posicionamento de um dispositivo móvel | |
| BR112019026818B1 (pt) | Método de codificação, método de decodificação, aparelho, aparelho de comunicações, terminal, estação base e mídia legível por computador | |
| BR102018011961B1 (pt) | Sistemas, métodos e meio não transitório legível por computador para analisar cores a partir de uma plataforma de mídia social | |
| BR112019024244B1 (pt) | Processos de fermentação de metano de alta produtividade | |
| BR112019023944B1 (pt) | Combinação farmacêutica para o tratamento de um câncer | |
| BR112019021396B1 (pt) | Processo para fabricação de pululano | |
| BR102018003507B1 (pt) | Sistema de isolamento de tensão de tambor de guincho | |
| BR112019016182B1 (pt) | Método para diagnosticar risco de revisão relacionado a implante | |
| BR112019014127B1 (pt) | Composição farmacêutica para tratamento de tumores | |
| BR112019017156B1 (pt) | Dispositivo, sistema e método de gerenciamento de recepção de pedido, e, meio de armazenamento legível por computador | |
| BR112019014017B1 (pt) | Dispositivo de medição da quantidade de oxigênio presente em um gás, e, módulo de separação de ar | |
| BR112020009459B1 (pt) | Método para indicar informações de domínio de frequência do conjunto de recursos de controle comum de informações mínimas remanescentes do sistema |